Announcements Trials

Browse Landscape

Phase

Phase 2 6 Phase 1 2 Phase EARLY_PHASE1 1 Phase 3 1

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Breast Neoplasms 24 Neoplasm Metastasis 9 Neoplasms by Site 2 Neoplasms 2 Breast Diseases 2 von Hippel-Lindau Disease 1 Unilateral Breast Neoplasms 1 Skin Diseases 1 Sarcoma 1 Recurrence 1 Locally Advanced (Inoperable) or Metastatic Breast Cancer 1 Hormone Receptor-Positive and HER2-Negative Advanced Breast Cancer 1 HR+/HER2- Breast Cancer 1 HER2+ Breast Cancer 1 Estrogen Receptor-Positive, HER2-Negative Advanced Breast Cancer 1 Carcinoma, Renal Cell 1 Breast Neoplasm Female 1 Breast Cancer Recurrent 1 Advanced Breast Cancer 1

Interventions

Doxorubicin 25 Ifosfamide 22 Radiotherapy 17 Etoposide 11 Vincristine 10 Cyclophosphamide 10 Filgrastim 8 Dactinomycin 8 Trabectedin 7 Chemotherapy, Adjuvant 5 pazopanib 4 Cisplatin 4 Topotecan 3 Radiation 3 Neoadjuvant Therapy 3 Irinotecan 3 Granulocyte Colony-Stimulating Factor 3 Dacarbazine 3 sargramostim 2 etoposide phosphate 2 eribulin 2 Observation 2 Methotrexate 2 Mesna 2 Imatinib Mesylate 2 Gemcitabine 2 Epirubicin 2 Docetaxel 2 Dexrazoxane 2 Carboplatin 2

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 3 × Sarcoma × palbociclib × Clear all

NCT03784014 2026-04-29

MULTISARC

Institut National de la Santé Et de la Recherche Médicale, France

Phase 3 Completed

Neoplasm Metastasis, Sarcoma

Data powered by HemOnc (CC BY 4.0) Colophon ⚡